Switch to:
Also traded in: Austria, Denmark, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 46.11
NVO's Cash-to-Debt is ranked lower than
57% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. NVO: 46.11 )
Ranked among companies with meaningful Cash-to-Debt only.
NVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 5.08 Max: 90.39
Current: 46.11
0.29
90.39
Equity-to-Asset 0.47
NVO's Equity-to-Asset is ranked lower than
72% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NVO: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
NVO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.62 Max: 0.73
Current: 0.47
0.42
0.73
Debt-to-Equity 0.01
NVO's Debt-to-Equity is ranked higher than
88% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NVO: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
NVO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.05 Max: 0.54
Current: 0.01
0.01
0.54
Interest Coverage 339.46
NVO's Interest Coverage is ranked lower than
79% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 339.46 )
Ranked among companies with meaningful Interest Coverage only.
NVO' s Interest Coverage Range Over the Past 10 Years
Min: 8.86  Med: 544.08 Max: 864.67
Current: 339.46
8.86
864.67
Piotroski F-Score: 5
Altman Z-Score: 12.02
Beneish M-Score: -2.44
WACC vs ROIC
9.70%
129.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 43.75
NVO's Operating Margin % is ranked higher than
96% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. NVO: 43.75 )
Ranked among companies with meaningful Operating Margin % only.
NVO' s Operating Margin % Range Over the Past 10 Years
Min: 27.18  Med: 36.9 Max: 45.81
Current: 43.75
27.18
45.81
Net Margin % 35.15
NVO's Net Margin % is ranked higher than
94% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. NVO: 35.15 )
Ranked among companies with meaningful Net Margin % only.
NVO' s Net Margin % Range Over the Past 10 Years
Min: 21.08  Med: 28.65 Max: 35.15
Current: 35.15
21.08
35.15
ROE % 84.28
NVO's ROE % is ranked higher than
99% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. NVO: 84.28 )
Ranked among companies with meaningful ROE % only.
NVO' s ROE % Range Over the Past 10 Years
Min: 29.61  Med: 57.72 Max: 84.28
Current: 84.28
29.61
84.28
ROA % 39.85
NVO's ROA % is ranked higher than
98% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. NVO: 39.85 )
Ranked among companies with meaningful ROA % only.
NVO' s ROA % Range Over the Past 10 Years
Min: 19.62  Med: 34.41 Max: 41.29
Current: 39.85
19.62
41.29
ROC (Joel Greenblatt) % 141.86
NVO's ROC (Joel Greenblatt) % is ranked higher than
96% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. NVO: 141.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 50.68  Med: 140.16 Max: 178.92
Current: 141.86
50.68
178.92
3-Year Revenue Growth Rate 10.10
NVO's 3-Year Revenue Growth Rate is ranked higher than
60% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NVO: 10.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.3  Med: 12.4 Max: 127.9
Current: 10.1
-46.3
127.9
3-Year EBITDA Growth Rate 13.60
NVO's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. NVO: 13.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.5  Med: 15.3 Max: 165.4
Current: 13.6
-49.5
165.4
3-Year EPS without NRI Growth Rate 15.20
NVO's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NVO: 15.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 16.7 Max: 36.9
Current: 15.2
1.3
36.9
GuruFocus has detected 1 Warning Sign with Novo Nordisk A/S NVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVO's 30-Y Financials

Financials (Next Earnings Date: 2018-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

NVO Guru Trades in Q2 2017

Ken Fisher 11,690,997 sh (+12.86%)
Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff Sold Out
Jim Simons 13,534,300 sh (-17.52%)
» More
Q3 2017

NVO Guru Trades in Q3 2017

Steven Cohen 149,400 sh (New)
Jim Simons 14,361,300 sh (+6.11%)
Ken Fisher 12,124,724 sh (+3.71%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
» More
Q4 2017

NVO Guru Trades in Q4 2017

Steven Cohen 295,863 sh (+98.03%)
Jim Simons 15,731,200 sh (+9.54%)
Ken Fisher 12,705,477 sh (+4.79%)
Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
» More
Q1 2018

NVO Guru Trades in Q1 2018

Jeremy Grantham 657,000 sh (New)
Jim Simons 17,091,300 sh (+8.65%)
Ken Fisher 13,129,657 sh (+3.34%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Add 3.34%0.03%$48.49 - $58.14 $ 48.62-7%13,129,657
Ken Fisher 2017-12-31 Add 4.79%0.04%$47.53 - $53.73 $ 48.62-4%12,705,477
Ken Fisher 2017-09-30 Add 3.71%0.03%$41.15 - $49.22 $ 48.628%12,124,724
Ken Fisher 2017-06-30 Add 12.86%0.09%$34.28 - $44.44 $ 48.6221%11,690,997
Ruane Cunniff 2017-06-30 Sold Out 0.01%$34.28 - $44.44 $ 48.6221%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:AMGN, NAS:GILD, NAS:CELG, ASX:CSL, NAS:BIIB, LSE:SHP, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:ALXN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV » details
Traded in other countries:NNOR.Austria, NOVO B.Denmark, NOVA.Germany, NVON.Mexico, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Headquarter Location:Denmark
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Top Ranked Articles about Novo Nordisk A/S

Report: Developing Opportunities within El Pollo Loco, Chemed, Novo Nordisk A/S, FactSet Research, Fair Isaac, and HCP — Future Expectations, Projections Moving into 2018
Jeremy Grantham Buys Facebook, Novo Nordisk Top buys are in high-quality companies with a proven track record of profitability
Investor Jeremy Grantham (Trades, Portfolio)’s Boston-based asset management firm established two major new positions in the early months of the year. Read more...
Emisphere Amends License Agreement with Novo Nordisk
Market Trends Toward New Normal in Novo Nordisk A/S, Brookfield Asset Management, Dun & Bradstreet, Goldcorp, NorthStar Asset Management Group, and IMAX — Emerging Consolidated Expectations, Analyst Ratings
Sanofi’s Recent R&D Business Decisions and Developments A quick overview of Sanofi's Business Decisions and Developments aimed to strengthen their portfolio and ensure long term growth and viability.
If you have been following Sanofi it is not a secret that the performance of its stock has much to be desired. Over the last five years, the S&P 500 index has gained nearly 80% in value while Sanofi has fallen approximately 20%. However, Sanofi has made three significant business decisions recently that I believe are worth a closer look and could be a sign of things to change in the future. Read more...
Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx Drugmaker expands reach in blood disease space
In its second big deal this month, French drugmaker Sanofi SA (XPAR:SAN) (NYSE:SNY) announced on Monday it is buying Belgian biotech company Ablynx NV (XBRU:ABLX) (NASDAQ:ABLX) for 3.9 billion euros ($4.8 billion). Read more...
5 Undervalued Stocks With Growing Book Value Margins of safety and rising book value per share
According to GuruFocus’ All-In-One Screener, the following companies have grown their book value per share (BV/S) over the past decade. Read more...
"Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support
Novo Nordisk Gets FDA Panel's OK for Diabetes Drug Group votes unanimously to recommend approval of drug to compete with Eli Lilly
Novo Nordisk A/S (NYSE:NVO) just announced that an FDA advisory panel has voted in favor of the approval of one of its lead diabetes assets and the company is picking up some favorable attention in the space on the back of the news. Read more...
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide

Ratios

vs
industry
vs
history
PE Ratio 19.48
NVO's PE Ratio is ranked higher than
66% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. NVO: 19.48 )
Ranked among companies with meaningful PE Ratio only.
NVO' s PE Ratio Range Over the Past 10 Years
Min: 12.13  Med: 22.71 Max: 34.41
Current: 19.48
12.13
34.41
Forward PE Ratio 19.34
NVO's Forward PE Ratio is ranked higher than
68% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. NVO: 19.34 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.48
NVO's PE Ratio without NRI is ranked higher than
67% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. NVO: 19.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.13  Med: 22.71 Max: 34.41
Current: 19.48
12.13
34.41
Price-to-Owner-Earnings 20.76
NVO's Price-to-Owner-Earnings is ranked higher than
66% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. NVO: 20.76 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.52  Med: 25.69 Max: 45.27
Current: 20.76
14.52
45.27
PB Ratio 16.83
NVO's PB Ratio is ranked lower than
86% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. NVO: 16.83 )
Ranked among companies with meaningful PB Ratio only.
NVO' s PB Ratio Range Over the Past 10 Years
Min: 4.6  Med: 13.72 Max: 31.9
Current: 16.83
4.6
31.9
PS Ratio 6.86
NVO's PS Ratio is ranked higher than
63% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 6.86 )
Ranked among companies with meaningful PS Ratio only.
NVO' s PS Ratio Range Over the Past 10 Years
Min: 3.14  Med: 6.18 Max: 10.99
Current: 6.86
3.14
10.99
Price-to-Free-Cash-Flow 26.04
NVO's Price-to-Free-Cash-Flow is ranked higher than
59% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. NVO: 26.04 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.75  Med: 24.19 Max: 41.01
Current: 26.04
12.75
41.01
Price-to-Operating-Cash-Flow 19.43
NVO's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. NVO: 19.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.65  Med: 19.44 Max: 32.48
Current: 19.43
10.65
32.48
EV-to-EBIT 15.39
NVO's EV-to-EBIT is ranked higher than
67% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. NVO: 15.39 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.9  Med: 17.2 Max: 25.7
Current: 15.39
10.9
25.7
EV-to-EBITDA 14.41
NVO's EV-to-EBITDA is ranked higher than
67% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. NVO: 14.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.2  Med: 16.5 Max: 23.6
Current: 14.41
10.2
23.6
EV-to-Revenue 6.66
NVO's EV-to-Revenue is ranked higher than
67% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. NVO: 6.66 )
Ranked among companies with meaningful EV-to-Revenue only.
NVO' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.9  Med: 6 Max: 10.9
Current: 6.66
2.9
10.9
PEG Ratio 1.35
NVO's PEG Ratio is ranked higher than
65% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. NVO: 1.35 )
Ranked among companies with meaningful PEG Ratio only.
NVO' s PEG Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.09 Max: 3.54
Current: 1.35
0.65
3.54
Shiller PE Ratio 30.92
NVO's Shiller PE Ratio is ranked higher than
68% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 44.16 vs. NVO: 30.92 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 24.74  Med: 42.42 Max: 67.93
Current: 30.92
24.74
67.93
Current Ratio 1.13
NVO's Current Ratio is ranked lower than
84% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. NVO: 1.13 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.95 Max: 3.09
Current: 1.13
1.04
3.09
Quick Ratio 0.77
NVO's Quick Ratio is ranked lower than
86% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. NVO: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.31 Max: 2.6
Current: 0.77
0.74
2.6
Days Inventory 317.87
NVO's Days Inventory is ranked lower than
86% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. NVO: 317.87 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 317.87
246.45
343.56
Days Sales Outstanding 54.14
NVO's Days Sales Outstanding is ranked lower than
52% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. NVO: 54.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 54.14
45.09
66.07
Days Payable 85.49
NVO's Days Payable is ranked higher than
68% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. NVO: 85.49 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 78.4  Med: 105.12 Max: 127.69
Current: 85.49
78.4
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.63
NVO's Dividend Yield % is ranked higher than
81% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 1.12 vs. NVO: 2.63 )
Ranked among companies with meaningful Dividend Yield % only.
NVO' s Dividend Yield % Range Over the Past 10 Years
Min: 1.02  Med: 1.67 Max: 4.17
Current: 2.63
1.02
4.17
Dividend Payout Ratio 0.50
NVO's Dividend Payout Ratio is ranked lower than
52% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 0.50 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.29  Med: 0.37 Max: 0.63
Current: 0.5
0.29
0.63
3-Year Dividend Growth Rate 19.10
NVO's 3-Year Dividend Growth Rate is ranked higher than
73% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. NVO: 19.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -30.8  Med: 16.7 Max: 37.7
Current: 19.1
-30.8
37.7
Forward Dividend Yield % 2.63
NVO's Forward Dividend Yield % is ranked higher than
80% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.09 vs. NVO: 2.63 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.22
NVO's 5-Year Yield-on-Cost % is ranked higher than
90% of the 308 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. NVO: 8.22 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.19  Med: 5.22 Max: 13.03
Current: 8.22
3.19
13.03
3-Year Average Share Buyback Ratio 2.60
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. NVO: 2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: 1.5 Max: 3
Current: 2.6
-13.6
3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 1215.50
NVO's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. NVO: 1215.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.79  Med: 28.13 Max: 1239.58
Current: 1215.5
11.79
1239.58
Price-to-Tangible-Book 18.56
NVO's Price-to-Tangible-Book is ranked lower than
82% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. NVO: 18.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 9.68 Max: 31.52
Current: 18.56
3.14
31.52
Price-to-Intrinsic-Value-Projected-FCF 1.65
NVO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. NVO: 1.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.37  Med: 2.24 Max: 7.38
Current: 1.65
1.37
7.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.68
NVO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
97% of the 30 Companies
in the Global Biotechnology industry.

( Industry Median: 1.64 vs. NVO: 0.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
NVO' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.48  Med: 0.9 Max: 1.14
Current: 0.68
0.48
1.14
Price-to-Median-PS-Value 1.11
NVO's Price-to-Median-PS-Value is ranked lower than
57% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. NVO: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47  Med: 0.79 Max: 1.68
Current: 1.11
0.47
1.68
Price-to-Peter-Lynch-Fair-Value 1.24
NVO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
70% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. NVO: 1.24 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NVO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.65  Med: 1.06 Max: 3.78
Current: 1.24
0.65
3.78
Price-to-Graham-Number 4.00
NVO's Price-to-Graham-Number is ranked lower than
65% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. NVO: 4.00 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.58  Med: 3.2 Max: 6.75
Current: 4
1.58
6.75
Earnings Yield (Greenblatt) % 6.47
NVO's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. NVO: 6.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 5.8 Max: 9.2
Current: 6.47
3.9
9.2
Forward Rate of Return (Yacktman) % 19.62
NVO's Forward Rate of Return (Yacktman) % is ranked higher than
79% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. NVO: 19.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 8.4  Med: 22.5 Max: 24.4
Current: 19.62
8.4
24.4

More Statistics

Revenue (TTM) (Mil) $17,496.78
EPS (TTM) $ 2.50
Beta0.69
Volatility19.88%
52-Week Range $41.03 - 58.37
Shares Outstanding (Mil)2,424.81 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 17,529 18,273 19,202
EBIT (Mil $) 7,442 7,830 8,303
EBITDA (Mil $) 7,974 8,404 8,876
EPS ($) 2.55 2.65 2.87
EPS without NRI ($) 2.55 2.65 2.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.33%
Dividends per Share ($) 1.29 1.38 1.52

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}